BACKGROUND
Urinary incontinence (UI) is a condition that can have significant welfare implications for both dogs and their owners and often requires long-term treatment, with associated costs. Despite its importance, contemporary, generalisable and reliable prevalence and risk factor data are lacking. These data are needed to identify at-risk animals and to improve preventative and/or treatment strategies for susceptible groups/individuals.
METHODS
A cohort of dogs with UI was identified from the VetCompass
Prospective, case-control clinical study. The concentration of urine NTx, was measured using a commercially available immunoassay previously validated in dogs. To correct for alterations in urine concentration and glomerular filtration rate, urine NTx excretion was expressed as a ratio with the urinary creatinine concentration. Dogs receiving glucocorticoids were divided into 4 subgroups based on glucocorticoid dose (mg/kg/day) and 5 subgroups based on duration of glucocorticoid administration. The urine NTx excretion was then compared between groups to determine the effect of duration and dose of glucocorticoids on bone resorption.
RESULTS
Urine NTx excretion was significantly higher in dogs receiving high doses of glucocorticoids (1.1-2.5mg/kg) when compared with control dogs (P<0.041). A significant difference was not identified between groups receiving lower doses of glucocorticoids and control dogs. Dogs in the early stages of their glucocorticoid therapy (2 days-1 month) had significantly higher urine NTx excretion compared with all other time groups (P<0.039).
CONCLUSIONS
Urine NTx excretion was significantly higher in dogs receiving high dose glucocorticoids as well as in dogs in the early stages of their therapy. These results indicate that as in humans, dogs receiving glucocorticoid therapy have changes in bone metabolism that may lead to secondary osteoporosis. Those dogs receiving glucocorticoid therapy may benefit from ongoing monitoring and ultimately therapy for osteoporosis, including calcium supplementation and bisphosphonates.
Programme by searching electronic patient records collected between September 2009 and September 2014, encompassing 120 participating primary-care veterinary practices. Prevalence and demographic data were extracted. Risk factors for presence of UI were investigated in a case-control study, applying univariable logistic regression (p<0.05).
